Novo Nordisk's CagriSema shows 25% weight loss in women in late-stage analysis
Novo Nordisk reported that its next-generation obesity drug CagriSema achieved 25% average weight loss in women with obesity or overweight in a post-completion analysis of late-stage trial data.
